EAM
SWTX

Exome Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Exome Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,700
Closed -$3.23M – 78
2024
Q3 		$3.23M Buy
+100,700
New +$3.76M 2.18% 17

Other funds holding SWTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Exome Asset Management's SWTX Position: Q4 2024 in Review

Exome Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 100,700 shares — an estimated $3.23M sold.

Exome Asset Management first reported a position in SWTX in Q3 2024 and held it in 1 quarter. The position peaked at $3.23M in Q3 2024. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

  • Exome Asset Management reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Exome Asset Management sold 100,700 SpringWorks Therapeutics shares in Q4 2024, an estimated $3.23M.
  • Exome Asset Management first reported a position in SpringWorks Therapeutics in Q3 2024 and held it in 1 quarter.
  • Exome Asset Management's SpringWorks Therapeutics position peaked at $3.23M in Q3 2024.
  • 216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Exome Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.